Effectiveness of Phenylefrine in Prevention of Hypotension During Spinal Anesthesia for Cesarean Delivery


Hypotension in patients who are taken to surgery, is a very frequent complication, when the spinal anesthetical technique is used, associating this with significant adverse effects that can lead to morbidity specially in the obstetric patient. The objective of the study is determine if the phenylephrine used of prophylactic form, achieved to prevent the appearance of hypotension in obstetric patients led to Caesarea under spinal anesthesia.

Full Title of Study: “Effectivenes of Phenylefrine in Prevention of Hypotension During Spinal Anesthesia for Cesarean Delivery: a Randomised Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Double (Participant, Care Provider)
  • Study Primary Completion Date: February 20, 2017

Detailed Description

Worldwide, the caesarean section is one of the surgical procedures most frequently performed, representing a challenge to the anesthesiologist, who must administer anesthesia to the mother with minimal effects in the newborn. For this reason, spinal anesthesia emerges as an important option in the management of the obstetrical patient who is going to be taken to Caesarea. The hypotension, is one of the most frequent events adverse associated to this technical anesthetic, represented a risk of complications both, in the mother as in the fetus, by this reason the anesthesiologist must implement different strategies to treat it when this be present. From there arises the necessity of establishing if the phenylephrine, a drug used to treat hypotension, when is administed prophylactically, allows to avoid this effect. We designed a randomized clinical trial in elderly patients over 18 years who are taken to Caesarea, where they formed two groups of patients, one that will administer a prophylactic infusion of phenylephrine compared with placebo, assessing the incidence of hypotension in the two groups and the adverse events most commonly associated with this.


  • Drug: Phenylephrine
    • prophylactic infusion of phenylephrine 40 mcg/min

Arms, Groups and Cohorts

  • Experimental: group 1
    • Phenylephrine 40 mcg/min, infusion during 5 minutes
  • Placebo Comparator: group 2
    • Saline solution 21 cc, infusion during 5 minutes

Clinical Trial Outcome Measures

Primary Measures

  • Hypotension
    • Time Frame: caesarean delivery

Secondary Measures

  • heart rate
    • Time Frame: caesarean delivery
  • Newborn APGAR
    • Time Frame: Turn off of the newly born: measured to the 1 and 5 minutes from the birth

Participating in This Clinical Trial

Inclusion Criteria

  • pregnant subjects who are to be delivered to cesarean section under subarachnoid anesthesia – Gestational age >37 weeks Exclusion Criteria:

Pregnant subjects with:

  • Hipertensive disorders in pregnancy – Acute fetal distress – Evidence of placental dysfunction – History of cardiovascular or cerebrovascular diseases – hypersensitivity to phenylephrine – Rejection of the patient

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Universidad Industrial de Santander
  • Provider of Information About this Clinical Study
    • Principal Investigator: Nelly Johanna Puentes Vega, Principal investigator – Universidad Industrial de Santander
  • Overall Official(s)
    • Hector MelĂ©ndez, Dr, Study Director, Universidad Industrial de Santander

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.